Silence Therapeutics’ (SLN) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Friday,Benzinga reports. The firm currently has a $35.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the company. BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research report on Friday. The Goldman Sachs Group lowered their price target on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research report on Friday, May 9th. Finally, Morgan Stanley lowered their price target on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $33.83.

Silence Therapeutics Price Performance

Shares of SLN stock opened at $5.33 on Friday. The stock has a market capitalization of $159.53 million, a PE ratio of -3.39 and a beta of 1.41. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $22.47. The business has a 50-day moving average of $4.13 and a 200 day moving average of $4.95.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. Analysts anticipate that Silence Therapeutics will post -1.77 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC raised its position in Silence Therapeutics by 274.1% during the 1st quarter. Walleye Capital LLC now owns 136,150 shares of the company’s stock valued at $384,000 after purchasing an additional 99,753 shares during the last quarter. Jump Financial LLC bought a new position in shares of Silence Therapeutics in the 1st quarter worth approximately $74,000. Woodline Partners LP raised its position in shares of Silence Therapeutics by 22.6% in the 4th quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock worth $3,431,000 after acquiring an additional 91,829 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of Silence Therapeutics by 18.6% in the 4th quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock worth $680,000 after acquiring an additional 15,500 shares in the last quarter. Finally, Redmile Group LLC raised its position in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after acquiring an additional 500,000 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.